Creatine for treatment of depression in type 2 diabetes
Principal Investigator: Perry Renshaw | |
Keywords: Depression , Creatine , Diabetes | Department: Adult Psychiatry |
IRB Number: 00101803 | Co Investigator: Lindsay Scholl |
Specialty: Psychiatry | |
Sub Specialties: Mood Disorders | |
Recruitment Status: Recruiting |
Contact Information
Lindsay Scholl
lindsay.scholl@utah.edu
8013864773
Brief Summary
The purpose of the study is to determine whether 12 weeks of dietary augmentation with oral 5g creatine daily reduces depressive symptoms in persons with type 1 or type 2 diabetes mellitus as measured by Hamilton Rating Scale for Depression (HAM-D). Secondary clinical outcomes will include evaluation of changes in glycemic control as measured by hemoglobin A1c scores and in diabetes self-care as measured by the Diabetes Self-Management Questionnaire (DSMQ). We also propose to examine changes in brain metabolism inferred from phosphorus-31 magnetic resonance spectroscopy (31P-MRS).
Inclusion Criteria
- Women age 20-64
- Current diagnosis of Major Depressive Disorder identified by the SCID-5-RV
- Current HAM-D score of > 16
-Current type 1 or type 2 diabetes as confirmed either by A1c > 6.5 or by clinical history and concurrent use of antidiabetic medications (metformin, sulfonylureas, insulin, or other commonly used agents).
- Diabetes type 1 or 2 present for at least one year
- Minimal risk of pregnancy based on post-menopausal status, hysterectomy, use of intrauterine contraceptive device or subdermal contraceptive implant, or regular use of two forms of as-needed birth control
Exclusion Criteria
- Current use of psychotropic agents except for as needed use of benzodiazepines or other hypnotics for anxiety or the use of trazodone < 200mg total daily dose for insomnia
- Diagnosis of bipolar disorder, schizophrenia, or schizoaffective disorder, identified by the SCID-5-RV
- History of or current diagnosis of acute kidney injury (AKI), chronic kidney disease (CKD) or end-stage renal disease (ESRD)
- Electrolyte disturbance (hypokalemia, hyperkalemia, hyponatremia, or hypernatremia) on screening basic metabolic panel
- History of cardiac disease or QTc >500ms on screening EKG
- History of seizure disorder
- Current serious suicide risk identified by the Columbia Severity Suicide Rating Scale
- Positive pregnancy test
- Breastfeeding
- Contraindication to an MRI scan
- Current incarceration